Chromosomal NUP98-PHF23 translocation is associated with an aggressive form of acute myeloid leukemia (AML) and poor survival rate. Here, we report the molecular mechanisms by which NUP98-PHF23 recognizes the histone mark H3K4me3 and is inhibited by small molecule compounds, including disulfiram that directly targets the PHD finger of PHF23 (PHF23PHD). Our data support a critical role for the PHD fingers of NUP98-PHF23, and related NUP98-KDM5A and NUP98-BPTF fusions in driving leukemogenesis, and demonstrate that blocking this interaction in NUP98-PHF23 expressing AML cells leads to cell death through necrotic and late apoptosis pathways. An overlap of NUP98-KDM5A oncoprotein binding sites and H3K4me3-positive loci at the Hoxa/b gene clusters and Meis1 in ChIP-seq, together with NMR analysis of the H3K4me3-binding sites of the PHD fingers from PHF23, KDM5A and BPTF, suggests a common PHD finger-dependent mechanism that promotes leukemogenesis by this type of NUP98 fusions. Our findings highlight the direct correlation between the abilities of NUP98-PHD finger fusion chimeras to associate with H3K4me3-enriched chromatin and leukemic transformation.
Posttranslational modifications (PTMs) of histones provide fundamental mechanisms for modulating gene expression and determining cellular identities during organismal development and cell lineage specification. Misregulation of these mechanisms is associated with a number of human diseases, including acute myeloid leukemia (AML)1. AML is a malignancy of myeloid precursor cells, which is characterized by uncontrolled cell proliferation and arrested terminal differentiation. Clinical studies have identified a direct link between the development of AML and aberrant activities of proteins that play pivotal roles in epigenetic processes through installing, removing, or binding histone PTMs. For instance, chromosomal rearrangements that produce fusion genes involving the histone H3 lysine 4 (H3K4)-specific methyltransferase MLL1 account for ~70% of infant leukemias and ~5–10% of childhood and adult AML cases2. A subset of AML cases shows abnormal chromosomal translocations that involve nucleoporin 98 (NUP98) and its fusion partners and components of the epigenetic machinery, such as KDM5A/JARID1A, NSD1, NSD3, LEDGF, BPTF, and PHF233,4,5,6,7,8,9. The fused chimeras activate HOX gene-dependent oncogenic programs and induce leukemic transformation in mice and in human hematopoietic stem cells4,8,9,10.
NUP98, a component of the nuclear pore complex, was found on nucleoplasmic and cytoplasmic domains of the complex and in the nuclear interior. The nuclear pool of NUP98 has been shown to associate with spherical speckles—the GLFG (glycine, leucine, phenylalanine, and glycine) bodies—and FRAP (fluorescence recovery after photobleaching) experiments reveal that NUP98 is highly mobile within the nucleus of living cells11. NUP98 contains multiple GLFG repeats in its N-terminus that are required for the association of NUP98 with the GLFG bodies (hence the name of the bodies)11, and the mobility of NUP98 is strongly coupled to ongoing transcription11,12. Recent structural analysis of the NUP98 GLFG repeat shows that the repeat forms kinked β sheets with the aromatic side chain of phenylalanine being involved in intra- and inter-sheet stabilization, whereby providing a mechanism for a low complexity aromatic-rich kinked segments (LARKS)-dependent oligomerization13.
The NUP98–PHF23 fusion was originally identified as a cryptic translocation in AML in 200714, and like other NUP98 fusion chimeras, NUP98–PHF23 translocation is associated with an aggressive disease course and poor survival15. We have previously shown that the expression of NUP98–PHF23 fusion leads to myeloid, erythroid, T-cell, and B-cell leukemia in mice, and that the treatment of NUP98–PHF23 cells with a small molecule compound disulfiram (DS) results in death of cells expressing NUP98–PHF23, likely due to disruption of the histone-binding activity of the PHF23 plant homeodomain (PHD) finger9. Despite the critical role of NUP98–PHF23 in leukemogenesis, which emphasizes the urgent need to develop chemotypes targeting this chimera, the structure–function relationship of PHF23 remains poorly characterized.
In this study, we report molecular mechanisms for the recognition of methylated histone H3K4 by the PHD finger of PHF23 and inhibition of this interaction by small molecule compounds DS and amiodarone (AD). Our data corroborate the critical role of the PHD finger of NUP98–PHF23 in driving leukemogenesis and demonstrate that blocking this interaction leads to cell death through necrotic and late apoptosis pathways. The NMR-derived mapping of binding interfaces suggests the mechanism by which DS acts on NUP98–PHF23 and on related NUP98–KDM5A and NUP98–BPTF fusions. Our results shed further light on the direct correlation between the capabilities of NUP98 fusion chimeras to associate with H3K4me3-enriched chromatin and leukemogenesis.
Results and discussion
The PHD finger of PHF23 selects for H3K4me3
In the NUP98–PHF23 chimera, the amino-terminal portion of NUP98 with multiple GLFG repeats is fused to the carboxy-terminal portion of PHF23 that contains a single PHD finger (PHF23PHD) (Fig. 1a, b). Although PHF23PHD was shown to associate with biotinylated H3K4me3 peptide in a pulldown experiment8, neither selectivity of this domain for histone H3 nor the binding mechanism is known. To determine preference of PHF23PHD for the H3K4 methylation state, we expressed and purified 15N-labeled PHF23PHD and examined its interactions with H3K4me3, H3K4me2, H3K4me1, and H3K4me0 peptides by 1H,15N heteronuclear single quantum coherence (HSQC) experiments (Fig. 1c). Titration of the H3K4me3 peptide (aa 1–12 of H3K4me3) into the NMR sample caused substantial chemical shift perturbations (CSP) in PHF23PHD. In addition to CSPs, a number of cross-peaks of the protein broadened and disappeared, indicating tight binding in intermediate exchange regime on the NMR time scale. Titration of H3K4me2 peptide led to an almost identical pattern of CSP, and the intermediate exchange regime again pointed to a strong interaction and binding affinity in a low micromolar range. In agreement, dissociation constants (Kds) for the complexes of PHF23PHD with the H3K4me3 and H3K4me2 peptides were found to be 2 and 8 μM, respectively, as measured by intrinsic tryptophan fluorescence (Fig. 1d, e). In contrast, H3K4me1 and H3K4me0 peptides induced CSP in PHF23PHD in fast exchange regime, and plotting these resonance changes against peptide concentration yielded Kds of 580 μM and 1.6 mM, respectively. These results suggest that PHF23PHD selects for the higher methylation state of H3K4 (tri- and dimethylated) and discriminates against monomethylated (H3K4me1) or unmodified H3. We note that the binding affinity of PHF23PHD toward H3K4me3/2 is in the range of binding affinities exhibited by the majority of epigenetic readers that bind to histone tails (1–50 μM)16,17,18. High selectivity of PHF23PHD toward H3K4me3 was corroborated by peptide pulldown assays (Fig. 1f). GST-tagged PHF23PHD was incubated with biotinylated histone H3 and H4 peptides either unmodified or containing mono, di- and tri-methylation marks commonly found in chromatin. We found that PHF23PHD recognizes methylated Lys4 of H3 but does not associate with any other methylation marks of H3 or H4 tested and that symmetric or asymmetric dimethylation of Arg2 does not affect binding of PHF23PHD to H3K4me3.
The aromatic cage of PHF23PHD can accommodate lysine mimetics
What is the mechanism underlying leukemic activity of NUP98–PHF23? A fast (~20 s) recovery after photobleaching of the NUP98 GLFG bodies11 suggests that the GLFG bodies have a liquid/gel like property. Moreover, NUP98–PHF23 fusion is also capable of associating with nuclear speckles though smaller in size19, and LARKS-dependent oligomerization is known to yield a liquid phase13,20,21. In the case of NUP98–PHF23, formation of the phase separated nuclear bodies/condensates through GLFG repeats oligomerization would result in high (~100-fold higher)13,20,21 concentration of the protein at certain genomic sites, furthering binding of PHF23PHD to H3K4me3 and causing aberrant transcriptional activation (Fig. 2a). To better understand the mechanism by which PHF23PHD recognizes the histone tail, we determined the protein structure. Although PHF23PHD was crystallized in the presence of H3K4me3 peptide, unexpectedly we obtained the structure in which the N-terminal sequence of one PHF23PHD molecule was bound to the second PHF23PHD molecule (Fig. 2b, Supplementary Fig. 1, and Supplementary Table 1). Alignment of this structure with the structures of other PHD fingers, such as of KDM5A and BPTF in complex with H3K4me3 peptides (see discussion below), revealed that the N-terminal sequence DLIT (residues 338–341 of PHF23PHD) and a preceding serine derived from the vector superimpose very well with H3K4me3 in the KDM5A and BPTF complexes. Much like H3K4me3, the SDLIT sequence is bound in an extended conformation and pairs with the β1 strand of PHF23PHD, which results in the formation of the three-stranded antiparallel β-sheet. The I340 side chain occupies the aromatic/hydrophobic cage of PHF23PHD consisting of F348, M353, and W362 with another hydrophobic residue, L339 being positioned to make an additional wall of the cage.
To gain insight into the interaction with H3K4me3 peptide, we assigned resonances of the protein backbone amides through collecting and analyzing three-dimensional triple resonance NMR spectra of uniformly 13C,15N-labeled PHF23PHD (Supplementary Fig. 2). Mapping the most perturbed residues of the protein (due to binding of H3K4me3) on the surface of PHF23PHD confirmed that H3K4me3 occupies the same binding pocket of PHF23PHD as the SDLIT sequence (Fig. 2c, d). The importance of the aromatic cage residues was confirmed by mutagenesis. Substitution of either M353 with valine or W362 with alanine abolished the interaction with H3K4me3, and replacement of F348 with alanine led to protein unfolding, suggesting a role of this residue in structural stability of PHF23PHD (Fig. 2e). Although PHF23PHD recognizes higher methylation states of H3K4 and interacts substantially weaker with H3K4me1 or unmodified H3K4, similar directional patterns of CSPs observed upon binding of each peptide imply that the aromatic cage can accommodate either methylated or unmodified lysine (Supplementary Fig. 3). Of note, I340 in the SDLIT sequence superimposes well with the hydrophobic part of the K4me3 side chain, further suggesting that lysine mimetics could also occupy the aromatic cage (Fig. 2b).
Amiodarone (AD) and disulfiram (DS) directly bind to PHF23PHD
Several small molecule compounds that target the PHD finger in NUP98–PHF23 and show promising results in inhibiting leukemogenesis have been identified, including the FDA approved antiarrhythmic drug AD and DS used for the treatment of chronic alcoholism, however, their mechanisms of action remain unclear9,22 (Fig. 3a). Furthermore, fluorescence assays reveal that the cancer-relevant mutations R345L and L358M (Cosmic) (both R345 and L358 are located far from the H3K4me3-binding site) do not disrupt binding of PHF23PHD to H3K4me3, reinforcing the idea that inhibition of the H3K4me3-PHF23PHD interaction might be beneficial in destroying cancer cells (Fig. 2d). To better understand the mechanism by which AD and DS act on NUP98–PHF23, we assayed these compounds by NMR titration experiments. Gradual addition of AD or DS to PHF23PHD induced small but significant CSPs in the protein, indicative of direct interactions (Fig. 3b, c). These results were in agreement with the reports demonstrating that AD and its analogues display inhibitory activity toward H3K4me3-binding domains, whereas some PHD fingers are sensitive to DS22. Treating a NUP98–PHF23 expressing cell line (748T) vs. control cell line (7298/2) with up to 2.2 μM AD for 96 h showed modest inhibition of 748T cell survival, however, treatment of a myeloid NUP98–PHF23 expressing (961C) cell line vs. control (189E6 and 32D) for 48 h with 2 μM DS showed robust inhibition (Fig. 3d–f), corroborating our previous findings9. Together, NMR and cell data suggest that while both compounds directly target PHF23PHD, DS elicits a much stronger effect than AD in NUP98–PHF23 expressing leukemia cells.
AD and DS mechanisms of action differ
To elucidate the molecular mechanisms underlying inhibitory effects of AD and DS, we plotted CSPs observed in 1H,15N HSQC spectra of PHF23PHD upon titration of the compounds (Fig. 3b, c) onto the protein surface and in parallel examined the reaction mixtures by electrophoresis. Close evaluation of the NMR titration experiments revealed that the most affected residues of PHF23PHD were located in and around its H3K4me3-binding pocket, implying that both compounds associate with PHF23PHD near the binding site, at least at the protein:compound ratio of 1:20 for AD and 1:2 for DS (Fig. 3g, h and Supplementary Fig. 4). Addition of excess DS (ratio of 1:3) or AD (ratio of 1:50) led to disappearance of amide resonances of PHF23PHD, indicating the formation of high molecular weight species that exceed detection limit of NMR. Subsequent analysis of the reaction mixtures by SDS-PAGE gel electrophoresis revealed distinct modes of action for these compounds. We observed a single band corresponding to the size of a monomeric protein in the PHF23PHD:AD sample resolved on a nonreducing SDS-PAGE gel (Supplementary Fig. 5). We concluded that at high concentrations, AD stimulates non-covalent oligomerization of PHF23PHD. In contrast, in the presence of DS, nonreducing SDS-PAGE gels showed a ladder of protein oligomers, clearly observed after 30 min incubation of PHF23PHD with DS at a protein:compound ratio of 1:3 (Fig. 3i). Markedly, the PHF23PHD ladder bands disappeared upon addition of the reducing agent, β-mercaptoethanol (β-ME). These results suggest that at high concentration and over time DS reacts with zinc chelating Cys residues of PHF23PHD generating covalently linked intermolecular oligomers (Fig. 4a). Although we cannot exclude the formation of the intramolecular intermediates, in either case the DS activity would result in eventual and permanent disruption of the PHF23PHD fold.
DS promotes NUP98–PHF23 fusion cell death through necrosis and late apoptosis
We previously used chromatin immunoprecipitation-sequencing (ChIP-seq) to demonstrate that a NUP98–PHF23 fusion protein colocalizes with H3K4me3 at a limited number of target sites, including Hoxa7, Hoxa9, Meis1, and Hoxb5; genes that are known to be important for hematopoietic stem and precursor cell function9. DS treatment of 961C cells that express a NUP98–PHF23 fusion showed rapid and profound downregulation of target gene (Hoxa5, Hoxa7, Hoxa9, Hoxa10, Hoxb5, and Meis1) mRNA expression within 6 h of treatment with 2 μM DS (Fig. 4b). Downregulation of these genes was accompanied by rapid death (>95% at 24 h through necrotic and late apoptosis pathways) of the NUP98–PHF23 expressing cells, but not of three control cell lines, including 188G3, 189E6, and 32D (Fig. 4c), underscoring again the selective targeting of the PHD finger in the NUP98–PHF23 fusion by DS.
Functional PHD finger is critical in leukemic transformation
Much like NUP98–PHF23, fusions of NUP98 with BPTF and KDM5A contain a single PHD finger in the C-terminal part of the chimeras (Fig. 5a). As shown in Fig. 5b, all three fusions efficiently induced immortalization and transformation of murine hematopoietic stem/progenitor cells (HSPCs). To assess the mechanistic role of the PHD fingers in these processes, we compared the structure of PHF23PHD with that of KDM5APHD (the third PHD finger of KDM5A)8 and BPTFPHD23. The aromatic cage of BPTFPHD appears to be the most complete, consisting of four aromatic residues that fully enclose the trimethylammonium group of lysine 4, whereas the aromatic cages of PHF23PHD and KDM5APHD, although having different topologies, both contain two aromatic residues (Fig. 5c, d). Despite the differences in aromatic cage architecture, the three domains exhibit similar binding affinities to H3K4me3 (Kds = 3, 2, and 0.9 μM for BPTF23, PHF23, and KDM5A8, respectively). To determine whether the PHD–H3K4me3 interaction per se is responsible for the leukemic transformations (Fig. 5b), we generated NUP98–BPTF chimeras harboring Y10A or W23A mutations that have been shown to abrogate BPTFPHD interaction with H3K4me323. In contrast to wild-type NUP98–BPTF fusion, the mutant NUP98–BPTF Y10A or NUP98–BPTF W23A fusions failed to induce the oncogenic transformation of hematopoietic stem/progenitors (Fig. 5e, f). These data together with previous findings that mutations in the aromatic cages of NUP98–KDM5A and NUP98–PHF23 abrogate their transforming ability8, point to the universal requirement of a functional PHD finger for leukemogenesis in this type of oncogenic chimeras.
NUP98–KDM5A is enriched at H3K4me3 regions and is sensitive to DS
We next carried out ChIP-seq experiments to map the genomic occupancy of NUP98–KDM5A as well as the histone methylation marks H3K4me3 and H3K27me3 in the AML cells (Fig. 6a, b and Supplementary Fig. 6a). We found that there is a strong overlap of NUP98–KDM5A oncoprotein binding sites and H3K4me3-positive loci (Supplementary Fig. 6b), as exemplified by the Hoxa/b gene clusters and Meis1 (Fig. 6a). However, H3K27me3, a gene repressive histone mark, was found to be absent from these AML-related genes (Fig. 6b), a pattern that we also observed in AML cells carrying NUP98–PHF239. Collectively, our data indicate an overall similar mode of action for these NUP98 fusions during AML development that depends on binding of their PHD fingers to H3K4me3, a mark enriched at promoters of actively transcribed genes. These results also suggest that the PHD finger-targeting chemotypes could inhibit the NUP98 fusions in unison. Indeed, the treatment of cells expressing NUP98–KDM5A with DS showed DS concentration dependent cell death, in which 1 μM DS treatment led to <~1% live cells after 24 h (Fig. 6c).
Conservation of the PHD finger-dependent inhibition
To gain mechanistic insights into PHD finger-dependent inhibition, we investigated the effect of DS and AD on KDM5APHD and BPTFPHD by NMR and electrophoresis (Supplementary Figs. 7 and 8). As in the case of PHF23PHD, significant CSPs were observed in HSQC spectra of 15N-labeled KDM5APHD and BPTFPHD upon addition of DS, indicating binding of the compound (Fig. 6d, e). In contrast to the uniform disappearance of NMR signals observed for PHF23PHD at a protein:compound ratio of 1:3, resonances of KDM5APHD and BPTFPHD were still visible at this ratio and, additionally, a set of new cross-peaks emerged in the middle of the spectrum between 7.5 and 8.5 ppm in the 1H dimension, likely representing resonances of unfolded protein conformations. In agreement, SDS-PAGE gel assays showed formation of disulfide-bonded oligomers in BPTFPHD and KDM5APHD, implying that DS interacts with these PHD fingers through a conserved mechanism via generating cysteine-dependent disulfide species (Supplementary Fig. 8). We note that in addition to zinc-coordinating Cys residues, KDM5APHD contains an extra free cysteine, which likely contributes to the formation of primarily a dimer. Nevertheless, our data suggest that DS is capable of binding to PHD fingers and reacting with their either free or zinc-coordinating Cys residues, disrupting the structures and therefore histone-binding activities of all three NUP98 fusions.
Concluding remarks and future directions
Aberrations in histone methylation-dependent cellular processes have emerged as a common oncogenic pathway in human AML. Particularly, chromosomal translocations NUP98–PHF23, NUP98–KDM5A, and NUP98–BPTF define a subset of AMLs that are characterized by abnormal expression of Hoxa/b genes and Meis1. AMLs with such stemness-related gene signatures are highly lethal, underscoring an urgent need for the development of effective and specific anti-AML therapies. Our finding that NUP98–KDM5A directly binds to H3K4me3-marked “stemness” genes is consistent with previously observed occupancy of NUP98–PHF239 and suggests a common mechanism of action for NUP98 chimeras fused with the PHD finger-containing regions of KDM5A, PHF23, and BPTF (Fig. 1b). Because disruption of the H3K4me3-binding sites of the PHD fingers in these NUP98 fusions suppresses oncogenic transformation, the strategy to develop inhibitors of the PHD finger has a strong rationale. Importantly, targeting this H3K4me3-specific reader could also be beneficial for coinciding blocking of all three oncogenic proteins. Histone readers are increasingly considered to be druggable, and a number of potent inhibitors of acetyllysine recognizing bromodomain and YEATS domain have been developed in the past 10 years24,25,26,27. The pioneering studies8,9,22 uncovering the pivotal role of the histone binding by the PHD finger of KDM5A, PHF23, and BPTF in NUP98 fusions in leukemic transformation and the feasibility of targeting these fusions by small molecules together with our mechanistic findings further suggest that impairing the PHD finger function and/or structure may provide an effective way to treat AMLs associated with these NUP98 fusions.
Protein expression and purification
The human PHF23 PHD domain (aa 338–393) was cloned into a pGEX 6p-1 vector. Proteins were expressed in BL21 (DE3) RIL in LB or minimal media supplemented with 15NH4Cl, 13C-glucose and 0.05 mM ZnCl2. Protein expression was induced with 0.2 mM IPTG for 16 h at 16 °C. The GST-tagged proteins were purified on glutathione Sepharose 4B beads (GE Healthcare) in 20 mM Tris-HCl (pH 7.0) buffer, supplemented with 150 mM NaCl, and 5 mM DTT. The GST tag was cleaved overnight at 4 °C with PreScission or Thrombin protease. Proteins were further purified by size exclusion chromatography and concentrated in Millipore concentrators. All mutants were generated by site-directed mutagenesis using the Stratagene QuikChange mutagenesis protocol, grown and purified as wild-type proteins. Primers are listed in Supplementary Table 2.
NMR experiments were carried out at 298 K on Varian INOVA 500 and Bruker 600 MHz spectrometers. NMR samples contained 0.1 mM uniformly 15N-labeled WT or mutated PHD in PBS buffer (pH 6.5), 1 mM TCEP, and 8% D2O. Binding was characterized by monitoring chemical shift changes in the proteins induced by histone H3 peptides (synthesized by SynPeptide). The Kd values were determined by a nonlinear least-squares analysis in Kaleidagraph using the following equation:
where [L] is concentration of the peptide, [P] is the concentration of the protein, Δδ is the observed chemical shift change, and Δδmax is the normalized chemical shift change at saturation. Normalized chemical shift changes were calculated using the equation as follows:
where Δδ is the change in chemical shift in parts per million.
The chemical shift assignments were obtained by a set of triple resonance experiments with nonlinear sampling using a 1.7 mM 13C/15N-labeled PHF23PHD sample in 20 mM Tris (pH 7.0) buffer supplemented with 150 mM NaCl, 5 mM DTT, and 8% D2O as described28. Spectra were processed and analyzed with NMRPipe and CcpNmr Suite. Sequence-specific assignments were obtained using CcpNMR Analysis v2.1 and validated in the I-PINE web server.
For NMR titration experiments with inhibitors, 0.1 mM uniformly 15N-labeled PHF23PHD, BPTFPHD, or KDM5APHD was used. BPTFPHD (aa 225–230) and KDM5APHD (aa 1609–1659) were expressed and purified similar to PHF23PHD. All experiments with AD were carried out in 20 mM Tris-HCl (pH 7.0) buffer, supplemented with 150 mM NaCl, 5 mM DTT, and 8% D2O. A concentrated stock of AD (100 mM) was made in methanol and pH was adjusted to 7.0. For experiments with DS, DTT was removed from protein samples by buffer exchange. A concentrated stock of DS (25 mM) was made in DMSO. All histograms were generated by calculating the normalized chemical shift change per residue between apo and ligand-bound protein states.
Purified PHF23PHD was concentrated to 6–8 mg/ml in a buffer containing 20 mM Tris-HCl (pH 7.4) and 1 mM TCEP. Initial crystallization trials were set using the sitting-drop vapor-diffusion method. Good quality diffracting crystals were obtained at 18 °C by hanging drop vapor diffusion in 0.1 M Tris pH 8.65 and 25% tert-butanol. The data set was collected to 2.9 Å using the University of Colorado Denver Rigaku X-ray homesource. The phases were determined by molecular replacement in the CCP4 suite Phaser program using the PDB model 3O70. Model building was performed using Coot v0.8.229, and the structure was refined using Phenix Refine v1.630. The final structure was verified by MOLProbity31. The X-ray diffraction and structure refinement statistics are summarized in Supplementary Table S1.
Peptide pulldown assay
For the peptide pulldown assays, 1 µg of biotinylated histone peptides with different modifications was incubated with 1.5 µg of GST-fused proteins in binding buffer (50 mM Tris-HCl 7.5, 250 mM NaCl, 0.1% NP-40) overnight. Streptavidin beads (Amersham) were added to the mixture, and the mixture was incubated for 1 h with rotation. The beads were then washed three times and analyzed using SDS-PAGE and western blotting using anti-GST (sc-459) at 1/2000 dilution.
Spectra were recorded at 25 °C on a Fluoromax-3 spectrofluorometer (HORIBA). The samples containing 2.0 µM PHF23PHD fragment and progressively increasing concentrations of the peptide were excited at 295 nm. Experiments were performed in PBS buffer (pH 6.5) supplemented with 1 mM TCEP. Emission spectra were recorded over a range of wavelengths between 320 and 380 nm with a 1 nm step size and a 1 s integration time and averaged over three scans. The Kd values were determined using a nonlinear least-squares analysis and the equation as described32:
where [L] is the concentration of the peptide, [P] is the protein concentration, ΔI is the observed change of signal intensity, and ΔImax is the difference in signal intensity of the free and bound states of the PHD domain. The Kd value was averaged over three separate experiments, with error calculated as the standard deviation between the runs.
Samples containing 0.1 mM PHD finger proteins were incubated with DS for 10 min, 30 min, 1 h, 3 h, and overnight. The reactions were quenched by flash-freezing at indicated time points, and the samples were stored at −20 °C. After collecting all samples, frozen proteins were thawed and analyzed immediately by SDS-PAGE under nonreducing and reducing (10 mM β-ME) conditions. 10 μl of loading buffer (containing SDS, EDTA, glycerol, TRIS-HCl, and bromophenol blue) was added to 10 μl of protein samples. The samples were then loaded onto a 15% polyacrylamide gel and resolved. The gels were stained with Coomassie blue.
Cells and cell lines
Immortal, cytokine independent leukemic cell lines that express a NUP98–PHF23 fusion (748T and 961C) were established from NUP98–PHF23 transgenic mice9. 748T is a precursor T-cell line, and 961C is a myeloid cell line. 188G3 and 189E6 are IL-3-dependent cell lines established from embryonic stem cells that express a NUP98–HOXD13 fusion from the endogenous NUP98 locus33. 7298/2 is a precursor T-cell line established from SCL/LMO1 double transgenic mice34. 32D is an IL-3 dependent, spontaneously immortalized, murine myeloid cell line35. Murine AML lines transformed by NUP98–KDM5A were generated and maintained as previously described8. All cell lines were maintained in Iscove’s modified Dulbecco’s medium supplemented with 15–20% fetal bovine serum (FBS), 100 mM L-glutamine and 100 µg/mL penicillin/streptomycin (Invitrogen). 188G3, 189E6, and 32D cells were also supplemented with IL-3 (10 ng/mL) (Peprotech).
Apoptosis assays were conducted with an AnnexinV-FITC Apoptosis Detection Kit I (BD Pharmingen) using the manufacturer’s recommended protocol and a FACScan flow cytometer (Cytek Biosciences). Experiments were carried out as previously described9.
Primary murine hematopoietic stem/progenitor cells (HSPCs)
Primary bone marrow cells are harvested from femur and tibia of wild-type balb/C mice and then subject to a lineage-negative (Lin−) enrichment protocol to remove differentiated cell populations as described8. Such Lin− enriched HSPCs were first stimulated in the base medium (OptiMEM, Invitrogen, cat#31985), 15% of FBS (Invitrogen, cat#16000-044), 1% of antibiotics, and 50 μM of β-mercaptoethanol complemented with a cytokine cocktail that contains 10 ng/mL each of murine SCF (Peprotech), Flt3 ligand (Flt3L; Sigma), IL-3 (Peprotech), and IL6 (Peprotech) for 4 days. MSCV-based retrovirus encoding the NUP98-PHD finger fusion oncogene was produced in 293 cells. Two days postinfection with retrovirus, murine HSPCs were subject to drug selection and then plated for assaying proliferation and differentiation in the same liquid base medium with SCF alone as described8. These in vitro cultured HSPC cells were routinely monitored under microscopy and cellular morphology examined by Wright–Giemsa staining.
Chromatin immunoprecipitation followed by sequencing
ChIP-seq was carried out and ChIP-seq data alignment, filtration, peak calling and assignment, and cross-sample comparison were performed as described36. Mouse anti-Flag tag M2 (Sigma F1804, 5 μg), anti-H3K3me3 (ab9050, 5 μg), and anti-H3K27me3 (Millipore 07-449, 5 μg) were used.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Coordinates and structure factors for PHF23PHD have been deposited in the Protein Data Bank with accession code PDB 6WXK (https://doi.org/10.2210/pdb6WXK/pdb). The ChIP-seq data are submitted to GEO under the accession number GSE146693. All other relevant data supporting the key findings of this study are available within the article and its Supplementary Information files or from the corresponding authors upon reasonable request. The source data underlying Figs. 1d, f, 2b, d, 3d–f, 4b, c, 5f, and 6c are provided in the Source Data file.
Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457–469 (2010).
Milne, T. A. Mouse models of MLL leukemia: recapitulating the human disease. Blood 129, 2217–2223 (2017).
Gough, S. M., Slape, C. I. & Aplan, P. D. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 118, 6247–6257 (2011).
Wang, G. G., Cai, L., Pasillas, M. P. & Kamps, M. P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9, 804–812 (2007).
Ahuja, H. G. et al. t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF). Cancer Res. 60, 6227–6229 (2000).
Rosati, R. et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99, 3857–3860 (2002).
van Zutven, L. J. et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 45, 437–446 (2006).
Wang, G. G. et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 459, 847–851 (2009).
Gough, S. M. et al. NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function. Cancer Discov. 4, 564–577 (2014).
Cardin, S. et al. Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. Blood Adv. 3, 3307–3321 (2019).
Griffis, E. R., Altan, N., Lippincott-Schwartz, J. & Powers, M. A. Nup98 is a mobile nucleoporin with transcription-dependent dynamics. Mol. Biol. Cell 13, 1282–1297 (2002).
Capelson, M. et al. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 140, 372–383 (2010).
Hughes, M. P. et al. Atomic structures of low-complexity protein segments reveal kinked beta sheets that assemble networks. Science 359, 698–701 (2018).
Reader, J. C., Meekins, J. S., Gojo, I. & Ning, Y. A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia. Leukemia 21, 842–844 (2007).
Ning, Y. A cryptic translocation leading to NUP98-PHF23 fusion in AML. Best. Pract. Res Clin. Haematol. 29, 320–323 (2016).
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D. & Patel, D. J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14, 1025–1040 (2007).
Musselman, C. A., Lalonde, M. E., Cote, J. & Kutateladze, T. G. Perceiving the epigenetic landscape through histone readers. Nat. Struct. Mol. Biol. 19, 1218–1227 (2012).
Andrews, F. H., Strahl, B. D. & Kutateladze, T. G. Insights into newly discovered marks and readers of epigenetic information. Nat. Chem. Biol. 12, 662–668 (2016).
Fahrenkrog, B. et al. Expression of leukemia-associated Nup98 fusion proteins generates an aberrant nuclear envelope phenotype. PLoS ONE 11, e0152321 (2016).
Banani, S. F., Lee, H. O., Hyman, A. A. & Rosen, M. K. Biomolecular condensates: organizers of cellular biochemistry. Nat. Rev. Mol. Cell Biol. 18, 285–298 (2017).
Shin, Y. et al. Liquid nuclear condensates mechanically sense and restructure the genome. Cell 175, 1481–1491.e1413 (2018).
Wagner, E. K., Nath, N., Flemming, R., Feltenberger, J. B. & Denu, J. M. Identification and characterization of small molecule inhibitors of a plant homeodomain finger. Biochemistry 51, 8293–8306 (2012).
Li, H. et al. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 442, 91–95 (2006).
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
Wan, L. et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature 577, 121–126 (2020).
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384–400 (2012).
Li, X. et al. Structure-guided development of YEATS domain inhibitors by targeting pi-pi-pi stacking. Nat. Chem. Biol. 14, 1140–1149 (2018).
Mi, W. et al. The ZZ-type zinc finger of ZZZ3 modulates the ATAC complex-mediated histone acetylation and gene activation. Nat. Commun. 9, 3759 (2018).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 486–501 (2010).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 213–221 (2010).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 12–21 (2010).
Zhang, Y. et al. Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF. Nat. Commun. 10, 2314 (2019).
Slape, C., Chung, Y. J., Soloway, P. D., Tessarollo, L. & Aplan, P. D. Mouse embryonic stem cells that express a NUP98-HOXD13 fusion protein are impaired in their ability to differentiate and can be complemented by BCR-ABL. Leukemia 21, 1239–1248 (2007).
Chervinsky, D. S., Lam, D. H., Zhao, X. F., Melman, M. P. & Aplan, P. D. Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice. Leukemia 15, 141–147 (2001).
Ahmed, N. & Berridge, M. V. Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow-derived cell lines. Leuk. Res. 21, 609–618 (1997).
Ren, Z. et al. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood 134, 1176–1189 (2019).
This work was supported by the grants from NIH GM135671 and HL151334 to T.G.K., CA215284 to G.G.W., CA204020 to X.S. and by the Intramural Research Program of the National Cancer Institute, NIH ZIA SC0130378 and SC010379 to P.D.A. G.G.W. is an American Cancer Society Research Scholar and a Leukemia and Lymphoma Society Scholar. X.S. is a Leukemia & Lymphoma Society Career Development Program Scholar. Y.Z. is supported by NIH K99CA241301.
The authors declare no competing interests.
Peer review information Nature Communications thanks Christopher Douse and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhang, Y., Guo, Y., Gough, S.M. et al. Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion. Nat Commun 11, 3339 (2020). https://doi.org/10.1038/s41467-020-17098-4
This article is cited by
PHF23 promotes NSCLC proliferation, metastasis, and chemoresistance via stabilization of ACTN4 and activation of the ERK pathway
Cell Death & Disease (2023)
Nature Reviews Cancer (2021)